$54.72
8.28% yesterday
Nasdaq, Nov 15, 10:10 pm CET
ISIN
US22663K1079
Symbol
CRNX
Sector
Industry

Crinetics Pharmaceuticals Inc Stock price

$54.72
-2.88 5.00% 1M
+4.23 8.38% 6M
+19.14 53.79% YTD
+25.84 89.47% 1Y
+27.73 102.74% 3Y
+36.16 194.83% 5Y
+30.21 123.26% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-4.94 8.28%
ISIN
US22663K1079
Symbol
CRNX
Sector
Industry

Key metrics

Market capitalization $5.07b
Enterprise Value $4.26b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.31
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-307.81m
Free Cash Flow (TTM) Free Cash Flow $-203.56m
Cash position $862.67m
EPS (TTM) EPS $-3.72
P/E forward negative
P/S forward 3,371.78
EV/Sales forward 2,863.25
Short interest 7.86%
Show more

Is Crinetics Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Crinetics Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Crinetics Pharmaceuticals Inc forecast:

Buy
93%
Hold
7%

Financial data from Crinetics Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 2.26 2.26
55% 55%
-
-2.26 -2.26
201% 201%
-
- Selling and Administrative Expenses 86 86
71% 71%
-
- Research and Development Expense 217 217
37% 37%
-
-306 -306
45% 45%
-
- Depreciation and Amortization 2.26 2.26
55% 55%
-
EBIT (Operating Income) EBIT -308 -308
46% 46%
-
Net Profit -278 -278
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Crinetics Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Crinetics Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
one day ago
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025
Neutral
Seeking Alpha
3 days ago
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Marc Wilson - Chief Financial Officer Dana Pizzuti - Chief Medical and Development Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Cory Jubinvil...
Neutral
GlobeNewsWire
3 days ago
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025
More Crinetics Pharmaceuticals Inc News

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Scott Struthers
Employees 290
Founded 2008
Website www.crinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today